Biolife Solutions Stock Analysis

BLFS Stock  USD 27.06  0.29  1.08%   
BioLife Solutions is overvalued with Real Value of 22.79 and Target Price of 24.43. The main objective of BioLife Solutions stock analysis is to determine its intrinsic value, which is an estimate of what BioLife Solutions is worth, separate from its market price. There are two main types of BioLife Solutions' stock analysis: fundamental analysis and technical analysis.
The BioLife Solutions stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. BioLife Solutions is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. BioLife Stock trading window is adjusted to America/New York timezone.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLife Solutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
For more information on how to buy BioLife Stock please use our How to Invest in BioLife Solutions guide.

BioLife Stock Analysis Notes

About 100.0% of the company shares are held by institutions such as insurance companies. The book value of BioLife Solutions was currently reported as 7.04. The company has Price/Earnings (P/E) ratio of 173.59. BioLife Solutions recorded a loss per share of 1.11. The entity had not issued any dividends in recent years. The firm had 1:14 split on the 29th of January 2014. BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington. Biolife Solutions operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 432 people. For more info on BioLife Solutions please contact Michael Rice at 425 402 1400 or go to https://www.biolifesolutions.com.

BioLife Solutions Quarterly Total Revenue

30.57 Million

BioLife Solutions Investment Alerts

BioLife Solutions had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 143.27 M. Net Loss for the year was (66.43 M) with profit before overhead, payroll, taxes, and interest of 54.07 M.
BioLife Solutions currently holds about 46.55 M in cash with (12.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.09.
BioLife Solutions has a frail financial position based on the latest SEC disclosures
Over 100.0% of the company shares are held by institutions such as insurance companies
Latest headline from thelincolnianonline.com: BioLife Solutions Stock Price Up 6.7 percent Heres What Happened

BioLife Solutions Upcoming and Recent Events

21st of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

BioLife Largest EPS Surprises

Earnings surprises can significantly impact BioLife Solutions' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-05-13
2021-03-31-0.04-0.030.0125 
2020-05-14
2020-03-31-0.02-0.010.0150 
2019-05-09
2019-03-310.040.03-0.0125 
View All Earnings Estimates

BioLife Solutions Environmental, Social, and Governance (ESG) Scores

BioLife Solutions' ESG score is a quantitative measure that evaluates BioLife Solutions' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of BioLife Solutions' operations that may have significant financial implications and affect BioLife Solutions' stock price as well as guide investors towards more socially responsible investments.

BioLife Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Geneva Capital Management2024-09-30
865.3 K
Dimensional Fund Advisors, Inc.2024-09-30
846.6 K
Geode Capital Management, Llc2024-09-30
842.8 K
Royce & Associates, Lp2024-09-30
825.1 K
Palisade Capital Management Llc2024-09-30
821.1 K
Granahan Investment Management Inc..2024-09-30
658.6 K
Morgan Stanley - Brokerage Accounts2024-06-30
584.3 K
Gagnon Securities Llc2024-09-30
569.4 K
Bank Of America Corp2024-06-30
544.1 K
Casdin Capital, Llc2024-09-30
8.7 M
Blackrock Inc2024-06-30
5.5 M
Note, although BioLife Solutions' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

BioLife Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.24 B.

BioLife Profitablity

The company has Profit Margin (PM) of (0.31) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.05) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.05.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.40)(0.42)
Return On Capital Employed(0.19)(0.20)
Return On Assets(0.16)(0.17)
Return On Equity(0.20)(0.21)

Management Efficiency

BioLife Solutions has return on total asset (ROA) of (0.0597) % which means that it has lost $0.0597 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1504) %, meaning that it created substantial loss on money invested by shareholders. BioLife Solutions' management efficiency ratios could be used to measure how well BioLife Solutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.42 in 2024. Return On Capital Employed is likely to drop to -0.2 in 2024. At this time, BioLife Solutions' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 306.7 M in 2024, whereas Intangible Assets are likely to drop slightly above 19.5 M in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 7.72  8.11 
Tangible Book Value Per Share 2.10  1.11 
Enterprise Value Over EBITDA(15.87)(16.66)
Price Book Value Ratio 2.10  2.00 
Enterprise Value Multiple(15.87)(16.66)
Price Fair Value 2.10  2.00 
Enterprise Value717.7 M753.6 M
The strategic decisions made by BioLife Solutions management significantly impact its financial stability and market performance. Evaluating these factors helps determine whether the stock is a worthwhile investment.
Operating Margin
(0.05)
Profit Margin
(0.31)
Beta
1.883
Return On Assets
(0.06)
Return On Equity
(0.15)

Technical Drivers

As of the 26th of November, BioLife Solutions shows the Risk Adjusted Performance of 0.0395, downside deviation of 3.94, and Mean Deviation of 2.75. BioLife Solutions technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm BioLife Solutions coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if BioLife Solutions is priced correctly, providing market reflects its regular price of 27.06 per share. Given that BioLife Solutions has jensen alpha of (0.06), we suggest you to validate BioLife Solutions's prevailing market performance to make sure the company can sustain itself at a future point.

BioLife Solutions Price Movement Analysis

Execute Study
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. BioLife Solutions middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for BioLife Solutions. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

BioLife Solutions Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioLife Solutions insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioLife Solutions' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioLife Solutions insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Troy Wichterman over three weeks ago
Disposition of 894 shares by Troy Wichterman of BioLife Solutions at 23.15 subject to Rule 16b-3
 
Aby Mathew over a month ago
Disposition of 10000 shares by Aby Mathew of BioLife Solutions at 2.06 subject to Rule 16b-3
 
Aby Mathew over a month ago
Disposition of 10000 shares by Aby Mathew of BioLife Solutions at 2.06 subject to Rule 16b-3
 
Aby Mathew over two months ago
Disposition of 10000 shares by Aby Mathew of BioLife Solutions at 2.06 subject to Rule 16b-3
 
Richardson Garrie over two months ago
Disposition of 3070 shares by Richardson Garrie of BioLife Solutions at 25.12 subject to Rule 16b-3
 
Aebersold Sarah over three months ago
Disposition of 3000 shares by Aebersold Sarah of BioLife Solutions at 21.03 subject to Rule 16b-3
 
Todd Berard over three months ago
Disposition of 10000 shares by Todd Berard of BioLife Solutions at 20.18 subject to Rule 16b-3
 
Todd Berard over six months ago
Disposition of 10000 shares by Todd Berard of BioLife Solutions at 22.67 subject to Rule 16b-3
 
Aebersold Sarah over six months ago
Disposition of 4 shares by Aebersold Sarah of BioLife Solutions at 12.37 subject to Rule 16b-3
 
Aebersold Sarah over six months ago
Disposition of 410 shares by Aebersold Sarah of BioLife Solutions at 16.5 subject to Rule 16b-3
 
Todd Berard over six months ago
Disposition of 10000 shares by Todd Berard of BioLife Solutions at 15.67 subject to Rule 16b-3
 
Aebersold Sarah over six months ago
Disposition of 4000 shares by Aebersold Sarah of BioLife Solutions at 17.65 subject to Rule 16b-3

BioLife Solutions Outstanding Bonds

BioLife Solutions issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioLife Solutions uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioLife bonds can be classified according to their maturity, which is the date when BioLife Solutions has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

BioLife Solutions Predictive Daily Indicators

BioLife Solutions intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioLife Solutions stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

BioLife Solutions Corporate Filings

8K
20th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
19th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
14th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
12th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
8th of November 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
13A
1st of November 2024
An amended filing to the original Schedule 13G
ViewVerify
F4
17th of October 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
20th of September 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify

BioLife Solutions Forecast Models

BioLife Solutions' time-series forecasting models are one of many BioLife Solutions' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioLife Solutions' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About BioLife Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how BioLife Solutions prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioLife shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BioLife Solutions. By using and applying BioLife Stock analysis, traders can create a robust methodology for identifying BioLife entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.46)(0.49)
Operating Profit Margin(0.49)(0.52)
Net Loss(0.46)(0.49)
Gross Profit Margin 0.33  0.55 

Current BioLife Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. BioLife analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. BioLife analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
24.43Strong Buy10Odds
BioLife Solutions current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most BioLife analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand BioLife stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of BioLife Solutions, talking to its executives and customers, or listening to BioLife conference calls.
BioLife Analyst Advice Details

BioLife Stock Analysis Indicators

BioLife Solutions stock analysis indicators help investors evaluate how BioLife Solutions stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading BioLife Solutions shares will generate the highest return on investment. By understating and applying BioLife Solutions stock analysis, traders can identify BioLife Solutions position entry and exit signals to maximize returns.
Begin Period Cash Flow19.5 M
Long Term Debt18.3 M
Common Stock Shares Outstanding43.7 M
Total Stockholder Equity337.7 M
Tax Provision127 K
Quarterly Earnings Growth Y O Y6.4
Property Plant And Equipment Net32.6 M
Cash And Short Term Investments51.7 M
Cash35.4 M
Accounts Payable6.9 M
Net Debt7.3 M
50 Day M A23.9952
Total Current Liabilities42.2 M
Other Operating Expenses214.1 M
Non Current Assets Total292.1 M
Forward Price Earnings250
Non Currrent Assets OtherM
Stock Based Compensation31.7 M

Additional Tools for BioLife Stock Analysis

When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.